Can Nectin-4 PET help personalise treatment for bladder cancer?
In this EMUC TV presentation, Prof. Lena Unterrainer discusses the emerging role of Nectin-4 PET as a novel molecular imaging approach that may overcome some of the limitations of conventional imaging and FDG PET. She explores how Nectin-4 PET could assess target expression throughout the body, support treatment selection for enfortumab vedotin, evaluate treatment response, and potentially identify patients for future Nectin-4-targeted radioligand therapies. While prospective validation is still needed, this innovative approach could represent an important step toward more personalised bladder cancer care.